193 related articles for article (PubMed ID: 38148412)
1. CAR-Aptamers Enable Traceless Enrichment and Monitoring of CAR-Positive Cells and Overcome Tumor Immune Escape.
Zhou H; Abudureheman T; Zheng WW; Yang LT; Zhu JM; Liang AB; Duan CW; Chen K
Adv Sci (Weinh); 2024 Mar; 11(10):e2305566. PubMed ID: 38148412
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD79b/CD3 bispecific antibody combined with CAR19-T cells for B-cell lymphoma treatment.
Zheng WW; Zhou H; Li P; Ye SG; Abudureheman T; Yang LT; Qing K; Liang AB; Chen KM; Duan CW
Cancer Immunol Immunother; 2023 Nov; 72(11):3739-3753. PubMed ID: 37707586
[TBL] [Abstract][Full Text] [Related]
3. A novel His-tag-binding aptamer for recombinant protein detection and T cell-based immunotherapy.
Yang LT; Abudureheman T; Zheng WW; Zhou H; Chen J; Duan CW; Chen KM
Talanta; 2023 Oct; 263():124722. PubMed ID: 37247456
[TBL] [Abstract][Full Text] [Related]
4. [Construction and evaluation of dual-effect cord blood natural killer cells expressing highaffinity PD-1 and chimeric antigen CD19 receptor].
Zhong H; Zou Q; Liu H; Wang X; DU S; Liang H; Wu Z; Ye J; Zou Q
Nan Fang Yi Ke Da Xue Xue Bao; 2021 Dec; 41(12):1877-1884. PubMed ID: 35012922
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells.
Otáhal P; Průková D; Král V; Fabry M; Vočková P; Latečková L; Trněný M; Klener P
Oncoimmunology; 2016 Apr; 5(4):e1115940. PubMed ID: 27141398
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic double-negative CAR-T cells inhibit tumor growth without off-tumor toxicities.
Vasic D; Lee JB; Leung Y; Khatri I; Na Y; Abate-Daga D; Zhang L
Sci Immunol; 2022 Apr; 7(70):eabl3642. PubMed ID: 35452255
[TBL] [Abstract][Full Text] [Related]
7. Self-driving armored CAR-T cells overcome a suppressive milieu and eradicate CD19
Webster B; Xiong Y; Hu P; Wu D; Alabanza L; Orentas RJ; Dropulic B; Schneider D
Mol Ther; 2021 Sep; 29(9):2691-2706. PubMed ID: 33974997
[TBL] [Abstract][Full Text] [Related]
8. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
Front Immunol; 2021; 12():665970. PubMed ID: 34475869
[TBL] [Abstract][Full Text] [Related]
9. Parallel CD19/CD20 CAR-Activated T-Cells Are More Effective for Refractory B-Cell Lymphoma In Vitro and In Vivo.
Yin Y; Zhang P; He L; Guo X; Wang H; Li J; Xu Q
Evid Based Complement Alternat Med; 2022; 2022():1227308. PubMed ID: 36034960
[TBL] [Abstract][Full Text] [Related]
10. A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines.
Schneider D; Xiong Y; Wu D; Nӧlle V; Schmitz S; Haso W; Kaiser A; Dropulic B; Orentas RJ
J Immunother Cancer; 2017; 5():42. PubMed ID: 28515942
[TBL] [Abstract][Full Text] [Related]
11. Compromised antigen binding and signaling interfere with bispecific CD19 and CD79a chimeric antigen receptor function.
Leung I; Templeton ML; Lo Y; Rajan A; Stull SM; Garrison SM; Salter AI; Smythe KS; Correnti CE; Srivastava S; Yeung CCS; Riddell SR
Blood Adv; 2023 Jun; 7(12):2718-2730. PubMed ID: 36469024
[TBL] [Abstract][Full Text] [Related]
12. Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials.
Ramanayake S; Bilmon I; Bishop D; Dubosq MC; Blyth E; Clancy L; Gottlieb D; Micklethwaite K
Cytotherapy; 2015 Sep; 17(9):1251-67. PubMed ID: 26212611
[TBL] [Abstract][Full Text] [Related]
13. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
[TBL] [Abstract][Full Text] [Related]
14. Monitoring anti-CD19 chimeric antigen receptor T cell population by flow cytometry and its consistency with digital droplet polymerase chain reaction.
Cheng J; Mao X; Chen C; Long X; Chen L; Zhou J; Zhu L
Cytometry A; 2023 Jan; 103(1):16-26. PubMed ID: 35875964
[TBL] [Abstract][Full Text] [Related]
15. Inducible secretion of IL-21 augments anti-tumor activity of piggyBac-manufactured chimeric antigen receptor T cells.
Štach M; Ptáčková P; Mucha M; Musil J; Klener P; Otáhal P
Cytotherapy; 2020 Dec; 22(12):744-754. PubMed ID: 32950390
[TBL] [Abstract][Full Text] [Related]
16. PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts.
Bishop DC; Xu N; Tse B; O'Brien TA; Gottlieb DJ; Dolnikov A; Micklethwaite KP
Mol Ther; 2018 Aug; 26(8):1883-1895. PubMed ID: 29861327
[TBL] [Abstract][Full Text] [Related]
17. A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy.
Zhang Y; Li S; Wang Y; Lu Y; Xu Y; Rao Q; Wang H; Xing H; Tian Z; Tang K; Lv L; Wang M; Wang J
Exp Hematol Oncol; 2022 Mar; 11(1):15. PubMed ID: 35317863
[TBL] [Abstract][Full Text] [Related]
18. Anti-CD19 CAR T Cells That Secrete a Biparatopic Anti-CLEC12A Bridging Protein Have Potent Activity Against Highly Aggressive Acute Myeloid Leukemia
Rennert PD; Dufort FJ; Su L; Sanford T; Birt A; Wu L; Lobb RR; Ambrose C
Mol Cancer Ther; 2021 Oct; 20(10):2071-2081. PubMed ID: 34253594
[TBL] [Abstract][Full Text] [Related]
19. Extracellular Vesicles Expressing CD19 Antigen Improve Expansion and Efficacy of CD19-Targeted CAR-T Cells.
Zhang Y; Ge T; Huang M; Qin Y; Liu T; Mu W; Wang G; Jiang L; Li T; Zhao L; Wang J
Int J Nanomedicine; 2023; 18():49-63. PubMed ID: 36636644
[TBL] [Abstract][Full Text] [Related]
20. T cells expressing CD5/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape.
Dai Z; Mu W; Zhao Y; Cheng J; Lin H; Ouyang K; Jia X; Liu J; Wei Q; Wang M; Liu C; Tan T; Zhou J
Signal Transduct Target Ther; 2022 Mar; 7(1):85. PubMed ID: 35332132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
